This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Thank you for standing by. Welcome to the Biopath Holdings, Inc. First Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star 1 on your telephone. Please, the advice of today's conference may be recorded. If you require any further assistance, please press star then 0. I would now like to hand the conference over to your host today, Will O'Connor with Stern Investor Relations. Please go ahead.
spk03: Thank you, Operator. Welcome to the Biopath Holdings conference call and webcast to review the company's first quarter 2022 financial results and to provide an update on recent pipeline and corporate developments. Earlier, we issued a press release which outlined the topics that we plan to discuss on today's call. The release is available at biopathholdings.com. With me today from Biopath are President and CEO Peter Nielsen and Senior Vice President of Finance, Accounting, and Administration, Anthony Price. Before we begin the call, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we urge you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Biopath's CEO, Peter Nielsen.
spk06: Thanks, Will. Good morning, everyone, and thank you for joining us. 2022 is off to a terrific start for Biopath, and I'm proud of the corporate and clinical progress we have made year to date. The advancements we have made and will continue to make bring us one step closer to our goal of developing meaningful medicines to aid in the fight against cancer. I'll begin with an important corporate highlight. Last month, we were excited to announce the appointment of Aileen Sherwood, to our board of directors. Aileen is principal of Scienta Communications, an independent communications consultancy providing strategic public relations and corporate communications counsel to life science companies. With her extensive background in biotechnology communications, Aileen synthesizes complex science into compelling messaging. which is instrumental in guiding our communications to both the clinical and financial communities. She has already brought valuable industry insight to our team that will be increasingly important as we advance our de-enabilized platform in the fight against cancer. Moving now to our clinical programs and our lead product candidate, Prexager Burrisen. We continue to make significant progress advancing stage two of our phase two clinical trial of plexigyboricin for the treatment of acute myeloid lipid Involving landscape for standard of care in AML. Despite these new therapies, there are still patients who are refractory or resistant, and those are the patients we aim to help. As standard of care evolved, we adapted our trial design to reflect these changes. The amended Stage 2 of this Phase 2 trial in AML is an open-label Phase 2 two-stage multicenter study of Prexabiracin in combination with Decitamin and Venetoclax in two cohorts of patients with previously untreated AML and relapsed-resistant AML. A third cohort includes treating relapsed-resistant AML patients who are venetoclax-resistant or intolerant with the two-drug combination of pretragerbericin and decitabine. The primary endpoint for this study will be the number of patients who achieved complete remission which includes complete remission with incomplete hematologic recovery and complete remission with partial hematology recovery. An interim analysis will be performed on each cohort to assess the safety and efficacy of the treatment. Next, I'd like to turn to our planned Phase I clinical trial of BP1001-A in patients with with advanced solid tumors, including ovarian, uterine, pancreatic, and hormone refractory breast cancer. BP1001-A, a fourth biopath drug candidate, is a modified product from Prexagiviricin sharing the same drug substance with enhanced nanoparticle properties. You will recall that last year, the FDA cleared our investigational new drug, or IND, application to initiate a Phase I-1B clinical trial of BP1001-A in patients with solid tumors, including ovarian, endometrial, pancreatic, and triple negative breast cancer. This trial will be conducted at several leading cancer centers and is planned initially to evaluate the safety of prextubaricin in solid tumor patients. Patients diagnosed with recurrent ovarian and endometrial cancer often have poor outcomes, and it is our hope that Prexager-Burson may provide clinical benefit for such patients. We look forward to bringing this exciting program into the clinic in the coming weeks. Turning now to BP1002, our second therapeutic candidate, which targets BCL2. As you know, BCL-2 is responsible for driving cell survival in up to 60% of all cancers. High expression of BCL-2 has been correlated with poor prognosis for patients diagnosed with AML. Venetoclax has also shown activity against anti-apoptotic protein BCL-2 and works by neutralizing the protein's BH3 domain. It is an approved treatment for chronic lymphocytic leukemia, or CLL, patients and untreated AML patients. However, with the exception of some patients treated with allogenetic hematopoietic cell transplantation, disease relapse invariably occurs, oftentimes due to BH3 domain mutation over time. BP1002 also targets the BCL2 protein group. However, BP1002 activity is based on blocking the BCL2 messenger RNA and not the BH3 domain. As a result, we believe that BP1002 could provide an alternative for venetoclax patients who have relapsed, including AML patients who previously received venetoclax treatments. We expect to initiate this clinical trial in coming weeks at several leading cancer centers in the United States, including the Medical College at Cornell University, the University of Texas MD Anderson Cancer Center, and the Georgia Cancer Center. A total of six evaluable patients will be treated with BP1002 monotherapy in a standard 3 plus 3 design, with a starting dose of 20 milligrams per square meter. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over 28 days. The Phase Ib portion of the study will commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with the cytamine in refractory relapsed AML patients. Finally, let's review the progress we've made with our third drug candidate, BP1003, which targets the STAT3 protein. STAT3 is a transcription factor that regulates various tumorigenic processes, such as tumor proliferation, metastasis, and drug resistance. Its overexpression and aberrant activation characterize many cancers, including breast, lung, ovarian, liver, and colon cancer. Activation of the STAT3 pathway in breast and ovarian cancer cells promotes tumor initiation, migration, and taxol resistance. STAT3 also contributes to resistance in colorectal cancer cells. Its role in numerous malignancies made STAT3 a potential cancer therapeutic agent. BP1003 is a novel liposome incorporated STAT3 antisense oligodeoxynucleotide that efficiently reduces STAT3 expression and enhances the sensitivity of breast and ovarian cancer cells to taxol. These results are in line with previous work in which BP1003 plus gemcitamin displayed enhanced antitumor activity in pancreatic ductal adenocarcinoma. Together, these results strongly suggest that BP1003 combination therapy is a novel strategy for patients with advanced solid tumors. In April, we were delighted to present supportive preclinical data from this program at the 2022 American Association for Cancer Research annual meeting. before an audience of world-leading cancer researchers and physicians. Dr. Maria Gagliardi, a research scientist on our team, highlighted preclinical studies of BP1003 in combination with paclitaxel or fluorouracil as a potential treatment against breast and ovarian cancer cell. We are particularly excited to launch our first in-human validation of this cutting-edge therapy and an especially challenging cancer indication that has limited treatment options. We are aiming to file an IND application for this very promising product candidate later this year. With that, I'll now turn the program over to Anthony Price for a brief review of our first quarter 2022 financials, along with balance sheet highlights. Anthony?
spk04: Thanks, Peter. The company reported a net loss of 3.4 million, or 47 cents per share, for the three months ended March 31st, 2022, compared to a net loss of 2.4 million, or 43 cents per share, for the three months ended March 31st, 2021. Research and development expense for the three months ended March 31st, 2022, increased to 2.1 million, compared to 1.3 million, for the three months ended March 31st, 2021, primarily due to increased clinical trial expenses for startup costs related to our phase one clinical trial of BP1002 in refractory relapsed AML patients and timing of activities for our phase one clinical trial of BP1002 in lymphoma. General and administrative expense for the three months ended March 31st, 2022 increased to $1.3 million compared to $1.2 million for the three months ended March 31, 2021, primarily due to increased stock-based compensation expense. As of March 31, 2022, the company had cash of $21.2 million compared to $23.8 million as of December 31, 2021. Net cash used in operating activities for the three months ended March 31, 2022 was $2.5 million compared to $1.6 million for the comparable period in 2021. With that, I will now turn the call back over to Peter. Thanks, Anthony.
spk06: Throughout the first quarter, we continued to advance our mission to deliver a better path for cancer patients. With ongoing progress across multiple of our de-enabilized antisense RNAi nanoparticle drug candidates, we are bringing a gentler solution to fight against cancers. As we look to the balance of the year, we expect to build on this with a number of value-creating milestones, including several clinical trial initiations, and I look forward to reporting our progress in the months ahead. With that, operator, we're ready to open the call for questions.
spk02: Thank you. If you have a question at this time, please press star then 1 on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. Again, if you have a question at this time, please press star, then 1. And our first question comes from the line of with HC Wainwright. Your line is open. Please go ahead.
spk05: Hi. Thank you for taking my questions. Could you give us a detailed update regarding the enrollment status of the three arms of the Phase II AMR trial?
spk06: The Phase II enrollment status, we're well in excess of 30, and the trial is really taking off pretty well. We're treating eight patients right now and have seven additional patients that are waiting for a slot. As drug supply ramps up from the problems we had during the pandemic, we expect to gain quite a bit of momentum as we get into the second half of this year.
spk05: Does any arm have the potential to reach 19 available patients during 2022? I think
spk06: Towards the end of the year, beginning in the first quarter, we expect to see getting to the point where we would be able to do interim evaluations to evaluate for accelerating the trials. So I think we're on schedule for that. Beginning at the end of the year or beginning in the first quarter.
spk05: Okay. And with respect to... the Phase I AML trial of BP1002, how long would it take the Phase I portion to complete?
spk06: Well, of course, that depends on enrollment. We have had a lot of interest. It's a 3 plus 3 trial, and we'll start out at 20, and we'd go 40, 60, 90, and... I don't know if we'd go beyond that. But that would be, I think, a year at least, depending on how fast. We have some really good institutions or sites that are interested. So there's been some solid interest in that because you know the need situation. AML patients who had been on venetoclax who – become resistant, uh, have been very short, uh, expectantly. So, uh, we're pushing to get that through. Uh, we hope to start that, uh, in this quarter. And, uh, uh, it's really a function of how quickly sites can turn around their contracts and IRB reviews and whatnot. Uh, it's been a general slowdown. They've had trouble with, uh, with people. So, uh, But that's a trial that could go pretty fast, but I can't give you an exact readout of timelines. There's a lot of variables in there that I don't control.
spk05: But how many sites could be actively enrolling patients by the end of this quarter?
spk06: Well, by the end of this quarter, maybe a couple. I think the goal is more, the people that we're working right now to sign up on that is... as many as four, and they're solid groups. MD Anderson and Cornell are both, I think, very interested in that, and quite frankly, so is UCLA.
spk05: Okay, okay. And with respect to BP1003, is there going to be any additional data to be presented during the remainder of 2022? Any preclinical data?
spk06: I think the plan on that, of course, I think I've mentioned that we had trouble with the, you know, you always want to start out and get the PK studies done, and those take detection of the substance in animals, and we think we have that resolved now, and that will allow us to We have to confirm that, but then we're going to do an additional rabbit tox study, and that will be the second species study we need for the IND. So the immediate goal is presenting the IND and hopefully having that submitted before the end of the year. Now, I could see where, you know, perhaps the rabbit study and whatnot, you know, that data might get presented. You know, I'm not sure whether the next candidate would be ASH for that, so I'm not sure if that would happen. But those are the clinical studies that would go on. So whether we do that by the end of the year, I'm not sure. Okay. All right. Thank you. Okay. Thank you, Yee.
spk02: Thank you. And again, if you have a question at this time, please press star then 1. And I'm showing no further questions, and I'd like to turn the conference back over to Peter Nielsen for any further remarks.
spk06: Thank you. And thank you, everyone, for joining us and for your continued support of Biopath. Have a great day.
spk02: This concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer